Replicor Inc.   Report issue

For profit Phase 2
Founded: Montreal QE Canada (1998)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2009
NCT02646163
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now